A stock I like
After reading The Black Swan: Second Edition: The Impact of the Highly Improbable: With a new section: "On Robustness and Fragility"
I convinced myself that every portfolio should have a collection of research oriented bio-pharmaceutical stocks.
Crucell (CRXL) is a dutch bio-pharmaceutical company that specializes in vaccines for infectious diseases. It was founded as a research lab and they merged with another company that had rights to many vaccines about 4 years ago, giving them a steady cashflow to finance their research. I think they're well positioned to hit a homerun.
I convinced myself that every portfolio should have a collection of research oriented bio-pharmaceutical stocks.
Crucell (CRXL) is a dutch bio-pharmaceutical company that specializes in vaccines for infectious diseases. It was founded as a research lab and they merged with another company that had rights to many vaccines about 4 years ago, giving them a steady cashflow to finance their research. I think they're well positioned to hit a homerun.
Labels: black swan, buy recommendation, diversification, dividend, geographic diversification, pharmaceutical
posted by Gary Carson at
7:59 PM
0 Comments
